Summary & Overview
HCPCS M0223: Bebtelovimab IV Injection with Home Monitoring
HCPCS Level II code M0223 represents the intravenous administration of bebtelovimab, including injection and post-administration monitoring performed in the patient’s home or residence. The code captures a home-based therapeutic monoclonal antibody service that gained prominence during the COVID-19 public health emergency and remains relevant for home infusion care models. Nationally, the code matters because it documents resource use and enables payment for clinician- or provider-administered COVID-19 monoclonal antibody treatment delivered outside traditional facility settings.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for bebtelovimab administration in home settings, guidance on common billing practices for home infusion services, and a summary of typical modifiers and service-line considerations. The publication also outlines benchmarks and policy updates relevant to home-based monoclonal antibody administration where available, and highlights documentation elements needed to support the bundled injection-plus-monitoring service captured by M0223.
Data not available in the input for specific payer reimbursement rates, associated taxonomies, or ICD-10 diagnoses.
Billing Code Overview
HCPCS Level II code M0223 describes an intravenous injection of bebtelovimab and includes both the injection and post-administration monitoring provided in the home or residence. The service encompasses administration and observation delivered at a beneficiary's private home, including a home that was made provider-based to a hospital during the COVID-19 public health emergency.
Service type: Therapeutic monoclonal antibody infusion/IV injection administered in the home.
Typical site of service: Patient's home or residence (home infusion/house call setting).
Clinical & Coding Specifications
Clinical Context
A home infusion nurse visits an adult beneficiary recently diagnosed with mild-to-moderate COVID-19 who is at high risk for progression to severe disease (for example, advanced age, immunocompromise, or multiple chronic comorbidities). The clinician orders a single-dose intravenous monoclonal antibody, bebtelovimab, to be administered in the patient’s home. Prior to infusion the nurse verifies identity, documents informed consent and allergies, assesses vital signs, and establishes IV access. The nurse prepares and administers M0223 per product monograph, observes the patient during and for a monitored post-administration period for infusion reactions, documents the infusion start and stop times, and provides discharge instructions. If the beneficiary’s residence is temporarily made provider-based to the hospital during the COVID-19 Public Health Emergency, the same home-based workflow and monitoring requirements apply under M0223. Typical workflow steps: pre-visit remote screening, in-home nursing visit for medication verification and IV administration, continuous clinical observation during infusion, post-infusion monitoring for adverse events, and documentation of administration, monitoring, and any interventions performed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |